Medicare Coverage Policy For COVID Drugs Underscores Importance Of Add-On Payments
Executive Summary
Part of a broad rule that also aims to fix a coverage gap for COVID-19 vaccines, the payment policy differs from NTAP in that manufacturers of COVID therapies won’t have to formally apply and the add-on payments will not take the cost of the COVID products into account.
You may also be interested in...
Vaccines For Uninsured Adults Initiative Proposed In Biden’s Federal Budget For 2023
Biden budget proposal also addresses consolidating all Medicare coverage for vaccines under Part B, providing Medicare and Medicaid 'explicit' authority to cover vaccines approved under emergency use authorizations without cost sharing, and increasing 340B spending on program oversight.
COVID-19 Vaccine Payment Codes Released; ‘Specificity’ Will Help Real World Tracking
American Medical Association announces reimbursement codes for the COVID-19 vaccines being developed by Pfizer/BioNTech and Moderna.
Future US Purchases Of Lilly’s Bamlanivimab Will Depend On Success Of Outpatient Infusion Process
HHS reverses course on cost sharing for the antibody and says patients will not have to pay. Operation Warp Speed will watch ‘extremely carefully’ to see if the health care system is able to adapt its practices to safely administer to the drug for COVID-19, officials say at a media briefing. FDA-authorized dose of the drug is not too low, Woodcock says.